Adtalem Global Education Announces Fiscal Fourth Quarter and Full Year 2023 Results
- 35% YoY growth in adjusted EPS
- Revenue of $364.6 million, up 1.1% YoY
- Achievement of a $60 million cost synergy program
- Repurchase of $127 million of shares
- Reduction of gross debt by $151 million
- FY 2024 guidance with revenue of $1,460 million to $1,520 million and adjusted EPS of $4.20 to $4.40
- None.
Results ahead of expectations
Continued improvement in total enrollment trends
FY 2023 diluted earnings per share
Raising lower end of Adjusted EPS guidance for FY 2024
Fourth quarter and full year highlights
-
Fourth quarter revenue
, up$364.6 million 1.1% and full year revenue , up$1,450.8 million 5.0% year-over-year -
Fourth quarter total student enrollment 75,735, down
2.5% year-over-year, a quarterly sequential improvement of over 60 basis points - Chamberlain University and Walden University strong demand led by nursing programs in the fourth quarter
-
Achieved two-year
cost synergy program$60 million -
Full year GAAP net income
, and full year adjusted EBITDA$93.4 million , up$343.4 million 4.5% year-over-year
Full year capital allocation
-
Repurchased
of shares against$127 million Board authorized share repurchase program in addition to settling the remaining$300 million against the March 2022 announced$13 million accelerated share repurchase program in FY 2023$150 million -
Gross debt reduced by
in FY 2023, net leverage 1.3x$151 million
Fiscal year 2024 guidance
-
Revenue
to$1,460 million $1,520 million -
Adjusted earnings per share
to$4.20 $4.40
“I am encouraged by the results we delivered this year. Adtalem is a systemically important component of the
Beard continued, “Our strong fourth quarter results bode well for fiscal 2024, with improving enrollment trends and the delivery of our two-year cost synergy program. We have conviction in the efficacy of our Growth with Purpose strategy and the confidence to continue to invest in expanding access to high quality academic programs that lead to rewarding careers, and collectively serve to address workforce shortages and inequity in healthcare delivery.”
Financial Highlights
Selected financial data for the three months ended June 30, 2023:
-
Revenue of
increased$364.6 million 1.1% compared with the prior year. -
Operating income was
, compared with$39.6 million in the prior year; adjusted operating income was$46.0 million , compared with$69.9 million in the prior year.$89.6 million -
Net income was
, compared with$22.2 million in the prior year; adjusted net income was$6.7 million , compared with$45.3 million in the prior year.$58.6 million -
Diluted earnings per share was
, compared with$0.50 in the prior year; adjusted earnings per share was$0.15 , compared with$1.03 in the prior year.$1.28 -
Adjusted EBITDA was
, compared with$83.3 million in the prior year; adjusted EBITDA margin was$104.7 million 22.8% compared with29.0% in the prior year.
Selected financial data for the full year ended June 30, 2023:
-
Revenue of
increased$1,450.8 million 5.0% compared with the prior year. -
Operating income was
, compared with$168.2 million in the prior year; adjusted operating income was$76.7 million , compared with$287.6 million in the prior year. Operating margin improved to$267.6 million 11.6% from5.6% and adjusted operating margin increased to19.8% from19.4% in the prior year. -
Net income was
, compared with$93.4 million in the prior year; adjusted net income was$311.0 million , an increase of$192.2 million 26.4% compared with in the prior year.$152.0 million -
Diluted earnings per share decreased to
from$2.05 in the prior year; adjusted earnings per share increased to$6.43 , up$4.21 35.4% compared with in the prior year.$3.11 -
Adjusted EBITDA was
, an increase of$343.4 million 4.5% compared with in the prior year; adjusted EBITDA margin was$328.6 million 23.7% compared with23.8% in the prior year.
Business Highlights
-
Adtalem’s medical and veterinary schools graduated more than 1,400 students at their May 2023 commencement. Medical students from 44 states and 22 countries and veterinary students from 44 states and 5 countries,
27% of which identified as underrepresented minorities in medicine (by race or ethnicity), were amongst the graduating class. -
Chamberlain University continues expanding access and solving for critical nursing shortages, opening its second
Georgia campus inStockbridge , outside ofAtlanta , with students starting in September 2023.Stockbridge campus, at capacity, will be able to serve as many as 600 students, including up to 200 who need the flexibility of an evening-and-weekend program. - As a pioneer in online learning, Walden University continues to pave the way, recently being recognized by the United States Distance Learning Association (USDLA) for International Distance Learning Awards in the Trendsetter, Research, and Teaching/Learning categories for 2023.
Segment Highlights
Chamberlain |
||||||||||||||||||
$ in millions |
|
Three Months Ended June 30, |
Year Ended June 30, |
|||||||||||||||
|
|
2023 |
2022 |
% Change |
2023 |
2022 |
% Change |
|||||||||||
Revenue |
|
$ |
144.5 |
$ |
140.2 |
3.0 |
% |
$ |
571.0 |
$ |
557.5 |
2.4 |
% |
|||||
Operating Income |
|
$ |
35.7 |
$ |
41.1 |
(13.2 |
)% |
$ |
134.7 |
$ |
124.4 |
8.3 |
% |
|||||
Adj. Operating Income |
|
$ |
35.7 |
$ |
41.7 |
(14.4 |
)% |
$ |
135.5 |
$ |
127.3 |
6.5 |
% |
|||||
Adj. EBITDA |
|
$ |
41.1 |
$ |
47.8 |
(14.1 |
)% |
$ |
157.5 |
$ |
152.5 |
3.3 |
% |
|||||
Total Students (1) |
|
|
33,284 |
|
32,891 |
1.2 |
% |
|
|
|
-
Total student enrollment increased
1.2% compared with the prior year, driven by continued growth in pre-licensure and post-licensure nursing programs as well as higher persistence.
Walden |
|||||||||||||||||||
$ in millions |
|
Three Months Ended June 30, |
|
Year Ended June 30, |
|||||||||||||||
|
|
2023 |
2022 |
% Change |
|
2023 |
2022 |
% Change |
|||||||||||
Revenue |
|
$ |
138.0 |
$ |
137.1 |
0.7 |
% |
|
$ |
533.7 |
$ |
485.4 |
|
10.0 |
% |
||||
Operating Income |
|
$ |
9.8 |
$ |
12.4 |
(21.2 |
)% |
|
$ |
35.9 |
$ |
(5.3 |
) |
NM |
|
||||
Adj. Operating Income |
|
$ |
32.2 |
$ |
35.8 |
(10.1 |
)% |
|
$ |
110.4 |
$ |
104.6 |
|
5.5 |
% |
||||
Adj. EBITDA |
|
$ |
35.3 |
$ |
39.0 |
(9.4 |
)% |
|
$ |
123.7 |
$ |
116.9 |
|
5.9 |
% |
||||
Total Students (1) |
|
|
37,582 |
|
39,470 |
(4.8 |
)% |
|
|
|
|
-
Total student enrollment decreased
4.8% compared with the prior year, primarily attributable to declines in non-healthcare programs and to a lesser extent to healthcare programs partially offset by higher persistence. Elimination of off-cycle start dates adversely impacted year-over-year total enrollment growth by2.4% .
Medical and Veterinary |
||||||||||||||||||
$ in millions |
|
Three Months Ended June 30, |
|
Year Ended June 30, |
||||||||||||||
|
|
2023 |
|
2022 |
|
% Change |
|
2023 |
|
2022 |
|
% Change |
||||||
Revenue |
|
$ |
82.1 |
$ |
83.4 |
(1.5 |
)% |
|
$ |
346.1 |
$ |
338.9 |
2.1 |
% |
||||
Operating Income |
|
$ |
10.5 |
$ |
14.0 |
(24.9 |
)% |
|
$ |
59.6 |
$ |
59.4 |
0.5 |
% |
||||
Adj. Operating Income |
|
$ |
10.8 |
$ |
19.0 |
(43.0 |
)% |
|
$ |
67.3 |
$ |
69.1 |
(2.6 |
)% |
||||
Adj. EBITDA |
|
$ |
14.7 |
$ |
23.3 |
(37.1 |
)% |
|
$ |
82.8 |
$ |
86.9 |
(4.7 |
)% |
||||
Total Students (1) |
|
|
4,869 |
|
5,304 |
(8.2 |
)% |
|
|
|
|
-
Total student enrollment decreased
8.2% compared with the prior year, primarily due to medical programs.
(1) |
Represents total students attending sessions during each institution’s most recent enrollment period in Q4 FY 2023 and Q4 FY 2022 |
Fiscal Year 2024 Outlook
Adtalem guidance for fiscal year 2024, reaffirms revenue in the range of
A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Adtalem's results in accordance with GAAP.
Conference Call and Webcast Information
Adtalem will hold a conference call to discuss its fiscal 2023 fourth quarter and full year results today at 4:00 p.m. CDT (5:00 p.m. EDT).
The call can be accessed by dialing +1 877-407-6184 (
Adtalem will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (
About Adtalem Global Education
Adtalem Global Education (NYSE: ATGE) is a national leader in post-secondary education and leading provider of professional talent to the healthcare industry. With a dedicated focus on driving strong outcomes that increase workforce preparedness, Adtalem empowers a diverse learner population to achieve their goals and make inspiring contributions to their communities. Adtalem is the parent organization of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. Adtalem’s family of institutions has more than 300,000 alumni and nearly 10,000 employees. Adtalem was named one of America’s Most Responsible Companies in 2021 and 2023 by Newsweek and Statista, and one of America’s Best Employers for Diversity in 2021 and 2022 by Forbes and Statista. Visit Adtalem.com for more information and follow on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Adtalem’s future growth. Forward-looking statements can also be identified by words such as “future,” “believe,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. These risk and uncertainties include the risk factors described in Item 1A. “Risk Factors” of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) and our other filings with the SEC. These forward-looking statements are based on information available to us as of the date any such statements are made, and Adtalem assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.
Adtalem Global Education Inc. Consolidated Balance Sheets (unaudited) (in thousands, except par value) |
||||||
|
|
|
|
|
|
|
|
|
June 30, |
||||
|
|
2023 |
|
2022 |
||
Assets: |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
273,689 |
|
$ |
346,973 |
Restricted cash |
|
|
1,386 |
|
|
964 |
Accounts receivable, net |
|
|
102,749 |
|
|
81,635 |
Prepaid expenses and other current assets |
|
|
100,715 |
|
|
127,532 |
Total current assets |
|
|
478,539 |
|
|
557,104 |
Noncurrent assets: |
|
|
|
|
|
|
Property and equipment, net |
|
|
258,522 |
|
|
289,926 |
Operating lease assets |
|
|
174,677 |
|
|
177,995 |
Deferred income taxes |
|
|
56,694 |
|
|
51,093 |
Intangible assets, net |
|
|
812,338 |
|
|
873,577 |
Goodwill |
|
|
961,262 |
|
|
961,262 |
Other assets, net |
|
|
68,509 |
|
|
119,283 |
Total noncurrent assets |
|
|
2,332,002 |
|
|
2,473,136 |
Total assets |
|
$ |
2,810,541 |
|
$ |
3,030,240 |
|
|
|
|
|
|
|
Liabilities and shareholders' equity: |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
81,812 |
|
$ |
57,140 |
Accrued payroll and benefits |
|
|
52,041 |
|
|
67,792 |
Accrued liabilities |
|
|
105,806 |
|
|
98,124 |
Deferred revenue |
|
|
153,871 |
|
|
149,810 |
Current operating lease liabilities |
|
|
37,673 |
|
|
50,781 |
Total current liabilities |
|
|
431,203 |
|
|
423,647 |
Noncurrent liabilities: |
|
|
|
|
|
|
Long-term debt |
|
|
695,077 |
|
|
838,908 |
Long-term operating lease liabilities |
|
|
163,441 |
|
|
177,045 |
Deferred income taxes |
|
|
26,068 |
|
|
25,554 |
Other liabilities |
|
|
37,416 |
|
|
73,700 |
Total noncurrent liabilities |
|
|
922,002 |
|
|
1,115,207 |
Total liabilities |
|
|
1,353,205 |
|
|
1,538,854 |
Commitments and contingencies |
|
|
|
|
|
|
Total shareholders' equity |
|
|
1,457,336 |
|
|
1,491,386 |
Total liabilities and shareholders' equity |
|
$ |
2,810,541 |
|
$ |
3,030,240 |
Adtalem Global Education Inc.
Consolidated Statements of Income (unaudited) (in thousands, except per share data) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
June 30, |
|
June 30, |
||||||||||||
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Revenue |
|
$ |
364,641 |
|
|
$ |
360,647 |
|
|
$ |
1,450,826 |
|
|
$ |
1,381,842 |
|
Operating cost and expense: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of educational services |
|
|
163,718 |
|
|
|
161,279 |
|
|
|
648,486 |
|
|
|
659,776 |
|
Student services and administrative expense |
|
|
153,296 |
|
|
|
133,115 |
|
|
|
586,009 |
|
|
|
566,494 |
|
Restructuring expense |
|
|
1,111 |
|
|
|
8,629 |
|
|
|
18,817 |
|
|
|
25,628 |
|
Business acquisition and integration expense |
|
|
6,959 |
|
|
|
11,661 |
|
|
|
42,661 |
|
|
|
53,198 |
|
Gain on sale of assets |
|
|
— |
|
|
|
— |
|
|
|
(13,317 |
) |
|
|
— |
|
Total operating cost and expense |
|
|
325,084 |
|
|
|
314,684 |
|
|
|
1,282,656 |
|
|
|
1,305,096 |
|
Operating income |
|
|
39,557 |
|
|
|
45,963 |
|
|
|
168,170 |
|
|
|
76,746 |
|
Interest expense |
|
|
(15,294 |
) |
|
|
(19,441 |
) |
|
|
(63,100 |
) |
|
|
(129,348 |
) |
Other income (expense), net |
|
|
3,664 |
|
|
|
(1,327 |
) |
|
|
6,965 |
|
|
|
1,108 |
|
Income (loss) from continuing operations before income taxes |
|
|
27,927 |
|
|
|
25,195 |
|
|
|
112,035 |
|
|
|
(51,494 |
) |
(Provision for) benefit from income taxes |
|
|
(4,377 |
) |
|
|
(24,058 |
) |
|
|
(10,283 |
) |
|
|
15,539 |
|
Income (loss) from continuing operations |
|
|
23,550 |
|
|
|
1,137 |
|
|
|
101,752 |
|
|
|
(35,955 |
) |
Discontinued operations: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss from discontinued operations before income taxes |
|
|
(1,730 |
) |
|
|
(2,521 |
) |
|
|
(8,464 |
) |
|
|
(986 |
) |
(Loss) gain on disposal of discontinued operations before income taxes |
|
|
— |
|
|
|
(520 |
) |
|
|
(3,576 |
) |
|
|
473,483 |
|
Benefit from (provision for) income taxes |
|
|
424 |
|
|
|
8,650 |
|
|
|
3,646 |
|
|
|
(125,551 |
) |
(Loss) income from discontinued operations |
|
|
(1,306 |
) |
|
|
5,609 |
|
|
|
(8,394 |
) |
|
|
346,946 |
|
Net income |
|
$ |
22,244 |
|
|
$ |
6,746 |
|
|
$ |
93,358 |
|
|
$ |
310,991 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Continuing operations |
|
$ |
0.54 |
|
|
$ |
0.03 |
|
|
$ |
2.27 |
|
|
$ |
(0.74 |
) |
Discontinued operations |
|
$ |
(0.03 |
) |
|
$ |
0.12 |
|
|
$ |
(0.19 |
) |
|
$ |
7.17 |
|
Total basic earnings per share |
|
$ |
0.51 |
|
|
$ |
0.15 |
|
|
$ |
2.08 |
|
|
$ |
6.43 |
|
Diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Continuing operations |
|
$ |
0.53 |
|
|
$ |
0.02 |
|
|
$ |
2.23 |
|
|
$ |
(0.74 |
) |
Discontinued operations |
|
$ |
(0.03 |
) |
|
$ |
0.12 |
|
|
$ |
(0.18 |
) |
|
$ |
7.17 |
|
Total diluted earnings per share |
|
$ |
0.50 |
|
|
$ |
0.15 |
|
|
$ |
2.05 |
|
|
$ |
6.43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic shares |
|
|
43,292 |
|
|
|
45,162 |
|
|
|
44,781 |
|
|
|
48,388 |
|
Diluted shares |
|
|
44,129 |
|
|
|
45,758 |
|
|
|
45,600 |
|
|
|
48,388 |
|
Adtalem Global Education Inc.
Consolidated Statements of Cash Flows (unaudited) (in thousands) |
||||||||
|
|
|
|
|
|
|
||
|
|
Year Ended June 30, |
||||||
|
|
2023 |
|
2022 |
||||
Operating activities: |
|
|
|
|
|
|
||
Net income |
|
$ |
93,358 |
|
|
$ |
310,991 |
|
Loss (income) from discontinued operations |
|
|
8,394 |
|
|
|
(346,946 |
) |
Income (loss) from continuing operations |
|
|
101,752 |
|
|
|
(35,955 |
) |
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
||
Stock-based compensation expense |
|
|
14,299 |
|
|
|
22,611 |
|
Amortization and impairments to operating lease assets |
|
|
48,470 |
|
|
|
44,748 |
|
Depreciation |
|
|
41,575 |
|
|
|
44,574 |
|
Amortization of intangible assets |
|
|
61,239 |
|
|
|
97,274 |
|
Amortization and write-off of debt discount and issuance costs |
|
|
9,129 |
|
|
|
42,654 |
|
Provision for bad debts |
|
|
32,999 |
|
|
|
27,141 |
|
Deferred income taxes |
|
|
(5,087 |
) |
|
|
(544 |
) |
Loss on disposals, accelerated depreciation, and impairments to property and equipment |
|
|
3,999 |
|
|
|
3,501 |
|
Gain on extinguishment of debt |
|
|
(71 |
) |
|
|
(2,072 |
) |
Loss on investments |
|
|
3,689 |
|
|
|
3,271 |
|
Gain on sale of assets |
|
|
(13,317 |
) |
|
|
— |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
(37,614 |
) |
|
|
(29,881 |
) |
Prepaid expenses and other current assets |
|
|
9,324 |
|
|
|
(2,827 |
) |
Accounts payable |
|
|
21,666 |
|
|
|
(15,724 |
) |
Accrued payroll and benefits |
|
|
(15,683 |
) |
|
|
(12,118 |
) |
Accrued liabilities |
|
|
241 |
|
|
|
(16,305 |
) |
Deferred revenue |
|
|
5,807 |
|
|
|
70,355 |
|
Operating lease liabilities |
|
|
(59,188 |
) |
|
|
(49,147 |
) |
Other assets and liabilities |
|
|
(17,545 |
) |
|
|
(27,554 |
) |
Net cash provided by operating activities-continuing operations |
|
|
205,684 |
|
|
|
164,002 |
|
Net cash used in operating activities-discontinued operations |
|
|
(2,776 |
) |
|
|
(153,401 |
) |
Net cash provided by operating activities |
|
|
202,908 |
|
|
|
10,601 |
|
Investing activities: |
|
|
|
|
|
|
||
Capital expenditures |
|
|
(37,008 |
) |
|
|
(31,054 |
) |
Proceeds from sales of marketable securities |
|
|
7,635 |
|
|
|
3,447 |
|
Purchases of marketable securities |
|
|
(1,508 |
) |
|
|
(3,624 |
) |
Proceeds from note receivable related to property sold |
|
|
46,800 |
|
|
|
— |
|
Payment for purchase of business, net of cash and restricted cash acquired |
|
|
— |
|
|
|
(1,488,054 |
) |
Cash received on DeVry University loan |
|
|
— |
|
|
|
10,000 |
|
Net cash provided by (used in) investing activities-continuing operations |
|
|
15,919 |
|
|
|
(1,509,285 |
) |
Net cash used in investing activities-discontinued operations |
|
|
— |
|
|
|
(3,287 |
) |
Proceeds from sale of business, net of cash transferred |
|
|
— |
|
|
|
960,768 |
|
Payment for working capital adjustment for sale of business |
|
|
(3,174 |
) |
|
|
— |
|
Net cash provided by (used in) investing activities |
|
|
12,745 |
|
|
|
(551,804 |
) |
Financing activities: |
|
|
|
|
|
|
||
Proceeds from exercise of stock options |
|
|
2,625 |
|
|
|
8,879 |
|
Employee taxes paid on withholding shares |
|
|
(4,592 |
) |
|
|
(2,834 |
) |
Proceeds from stock issued under Colleague Stock Purchase Plan |
|
|
608 |
|
|
|
535 |
|
Repurchases of common stock for treasury |
|
|
(123,133 |
) |
|
|
(120,000 |
) |
Payment on equity forward contract |
|
|
(13,162 |
) |
|
|
(30,000 |
) |
Proceeds from long-term debt |
|
|
— |
|
|
|
850,000 |
|
Repayments of long-term debt |
|
|
(150,861 |
) |
|
|
(1,079,713 |
) |
Payment of debt discount and issuance costs |
|
|
— |
|
|
|
(49,553 |
) |
Payment for purchase of redeemable noncontrolling interest of subsidiary |
|
|
— |
|
|
|
(1,790 |
) |
Net cash used in financing activities |
|
|
(288,515 |
) |
|
|
(424,476 |
) |
Net decrease in cash, cash equivalents and restricted cash |
|
|
(72,862 |
) |
|
|
(965,679 |
) |
Cash, cash equivalents and restricted cash at beginning of period |
|
|
347,937 |
|
|
|
1,313,616 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
275,075 |
|
|
$ |
347,937 |
|
Adtalem Global Education Inc.
Segment Information (unaudited) (in thousands) |
|||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Three Months Ended |
|
Year Ended |
|||||||||||||||||||||||||
|
|
June 30, |
|
June 30, |
|||||||||||||||||||||||||
|
|
|
|
|
|
|
|
Increase/(Decrease) |
|
|
|
|
|
|
|
Increase/(Decrease) |
|
||||||||||||
|
|
2023 |
|
2022 |
|
$ |
|
% |
|
2023 |
|
2022 |
|
$ |
|
% |
|
||||||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Chamberlain |
|
$ |
144,496 |
|
|
$ |
140,226 |
|
|
$ |
4,270 |
|
|
3.0 |
% |
|
$ |
571,034 |
|
|
$ |
557,536 |
|
|
$ |
13,498 |
|
2.4 |
% |
Walden |
|
|
138,010 |
|
|
|
137,068 |
|
|
|
942 |
|
|
0.7 |
% |
|
|
533,725 |
|
|
|
485,393 |
|
|
|
48,332 |
|
10.0 |
% |
Medical and Veterinary |
|
|
82,135 |
|
|
|
83,353 |
|
|
|
(1,218 |
) |
|
(1.5 |
)% |
|
|
346,067 |
|
|
|
338,913 |
|
|
|
7,154 |
|
2.1 |
% |
Total consolidated revenue |
|
$ |
364,641 |
|
|
$ |
360,647 |
|
|
$ |
3,994 |
|
|
1.1 |
% |
|
$ |
1,450,826 |
|
|
$ |
1,381,842 |
|
|
$ |
68,984 |
|
5.0 |
% |
Operating income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Chamberlain |
|
$ |
35,683 |
|
|
$ |
41,124 |
|
|
$ |
(5,441 |
) |
|
(13.2 |
)% |
|
$ |
134,685 |
|
|
$ |
124,414 |
|
|
$ |
10,271 |
|
8.3 |
% |
Walden |
|
|
9,809 |
|
|
|
12,442 |
|
|
|
(2,633 |
) |
|
(21.2 |
)% |
|
|
35,880 |
|
|
|
(5,306 |
) |
|
|
41,186 |
|
NM |
|
Medical and Veterinary |
|
|
10,477 |
|
|
|
13,957 |
|
|
|
(3,480 |
) |
|
(24.9 |
)% |
|
|
59,649 |
|
|
|
59,357 |
|
|
|
292 |
|
0.5 |
% |
Home Office and Other |
|
|
(16,412 |
) |
|
|
(21,560 |
) |
|
|
5,148 |
|
|
23.9 |
% |
|
|
(62,044 |
) |
|
|
(101,719 |
) |
|
|
39,675 |
|
39.0 |
% |
Total consolidated operating income |
|
$ |
39,557 |
|
|
$ |
45,963 |
|
|
$ |
(6,406 |
) |
|
(13.9 |
)% |
|
$ |
168,170 |
|
|
$ |
76,746 |
|
|
$ |
91,424 |
|
119.1 |
% |
Non-GAAP Financial Measures and Reconciliations
We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Adtalem’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:
Adjusted net income (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for deferred revenue adjustment, CEO transition costs, restructuring expense, business acquisition and integration expense, intangible amortization expense, gain on sale of assets, pre-acquisition interest expense, write-off of debt discount and issuance costs, gain on extinguishment of debt, litigation reserve, investment impairment, net tax benefit related to a valuation allowance release, and net loss (income) from discontinued operations.
Adjusted earnings per share (most comparable GAAP measure: earnings per share) – Measure of Adtalem’s diluted earnings per share adjusted for deferred revenue adjustment, CEO transition costs, restructuring expense, business acquisition and integration expense, intangible amortization expense, gain on sale of assets, pre-acquisition interest expense, write-off of debt discount and issuance costs, gain on extinguishment of debt, litigation reserve, investment impairment, net tax benefit related to a valuation allowance release, and net loss (income) from discontinued operations.
Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Adtalem’s operating income adjusted for deferred revenue adjustment, CEO transition costs, restructuring expense, business acquisition and integration expense, intangible amortization expense, litigation reserve, and gain on sale of assets. This measure is applied on a consolidated and segment basis, depending on the context of the discussion.
Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for net loss (income) from discontinued operations, interest expense, other (income) expense, net, provision for (benefit from) income taxes, depreciation and amortization, stock-based compensation, deferred revenue adjustment, CEO transition costs, restructuring expense, business acquisition and integration expense, litigation reserve, and gain on sale of assets. This measure is applied on a consolidated and segment basis, depending on the context of the discussion. Income taxes, interest expense, and other (income) expense, net is not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with operating income (loss).
Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures.
Net debt – Defined as long-term debt less cash and cash equivalents.
Net leverage – Defined as net debt divided by adjusted EBITDA.
A description of special items in our non-GAAP financial measures described above are as follows:
- Deferred revenue adjustment related to a revenue purchase accounting adjustment to record Walden’s deferred revenue at fair value.
- CEO transition costs related to acceleration of stock-based compensation expense.
- Restructuring expense primarily related to plans to achieve synergies with the Walden acquisition and real estate consolidations at Walden, Medical and Veterinary, and Adtalem’s home office. We do not include normal, recurring, cash operating expenses in our restructuring expense.
- Business acquisition and integration expense include expenses related to the Walden acquisition and certain costs related to growth transformation initiatives. We do not include normal, recurring, cash operating expenses in our business acquisition and integration expense.
- Intangible amortization expense on acquired intangible assets.
-
Gain on sale of Adtalem’s
Chicago, Illinois , campus facility. - Pre-acquisition interest expense related to financing arrangements in connection with the Walden acquisition, write-off of debt discount and issuance costs and gain on extinguishment of debt related to prepayments of debt, reserves related to significant litigation, and impairment of an equity investment.
- Net tax benefit related to a valuation allowance release.
- Net loss (income) from discontinued operations includes the operations of ACAMS, Becker, OCL, and EduPristine, including the after-tax gain on the sale of these businesses, in addition to costs related to DeVry University.
Adtalem Global Education Inc. Non-GAAP Operating Income by Segment (unaudited) (in thousands) |
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||||||||||||||||
|
|
June 30, |
|
June 30, |
||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
Increase/(Decrease) |
|
|
|
|
|
|
|
Increase/(Decrease) |
||||||||||||||
|
|
2023 |
|
2022 |
|
$ |
|
% |
|
2023 |
|
2022 |
|
$ |
|
% |
||||||||||||||
Chamberlain: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating income (GAAP) |
|
$ |
35,683 |
|
$ |
41,124 |
|
$ |
(5,441 |
) |
|
(13.2 |
)% |
|
$ |
134,685 |
|
$ |
124,414 |
|
$ |
10,271 |
|
|
8.3 |
% |
||||
Restructuring expense |
|
|
— |
|
|
572 |
|
|
(572 |
) |
|
|
|
|
818 |
|
|
2,838 |
|
|
(2,020 |
) |
|
|
||||||
Adjusted operating income (non-GAAP) |
|
$ |
35,683 |
|
$ |
41,696 |
|
$ |
(6,013 |
) |
|
(14.4 |
)% |
|
$ |
135,503 |
|
$ |
127,252 |
|
$ |
8,251 |
|
|
6.5 |
% |
||||
Operating margin (GAAP) |
|
|
24.7 |
% |
|
29.3 |
% |
|
|
|
|
|
|
23.6 |
% |
|
22.3 |
% |
|
|
|
|
||||||||
Operating margin (non-GAAP) |
|
|
24.7 |
% |
|
29.7 |
% |
|
|
|
|
|
|
23.7 |
% |
|
22.8 |
% |
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Walden: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating income (loss) (GAAP) |
|
$ |
9,809 |
|
$ |
12,442 |
|
$ |
(2,633 |
) |
|
(21.2 |
)% |
|
$ |
35,880 |
|
$ |
(5,306 |
) |
$ |
41,186 |
|
|
NM |
|
||||
Deferred revenue adjustment |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
8,561 |
|
|
(8,561 |
) |
|
|
||||||
Restructuring expense |
|
|
71 |
|
|
37 |
|
|
34 |
|
|
|
|
|
3,245 |
|
|
4,053 |
|
|
(808 |
) |
|
|
||||||
Intangible amortization expense |
|
|
12,303 |
|
|
23,307 |
|
|
(11,004 |
) |
|
|
|
|
61,239 |
|
|
97,274 |
|
|
(36,035 |
) |
|
|
||||||
Litigation reserve |
|
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
|
|
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
|
||||||
Adjusted operating income (non-GAAP) |
|
$ |
32,183 |
|
$ |
35,786 |
|
$ |
(3,603 |
) |
|
(10.1 |
)% |
|
$ |
110,364 |
|
$ |
104,582 |
|
$ |
5,782 |
|
|
5.5 |
% |
||||
Operating margin (GAAP) |
|
|
7.1 |
% |
|
9.1 |
% |
|
|
|
|
|
|
6.7 |
% |
|
(1.1 |
)% |
|
|
|
|
||||||||
Operating margin (non-GAAP) |
|
|
23.3 |
% |
|
26.1 |
% |
|
|
|
|
|
|
20.7 |
% |
|
21.5 |
% |
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Medical and Veterinary: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating income (GAAP) |
|
$ |
10,477 |
|
$ |
13,957 |
|
$ |
(3,480 |
) |
|
(24.9 |
)% |
|
$ |
59,649 |
|
$ |
59,357 |
|
$ |
292 |
|
|
0.5 |
% |
||||
Restructuring expense |
|
|
353 |
|
|
5,034 |
|
|
(4,681 |
) |
|
|
|
|
7,687 |
|
|
9,791 |
|
|
(2,104 |
) |
|
|
||||||
Adjusted operating income (non-GAAP) |
|
$ |
10,830 |
|
$ |
18,991 |
|
$ |
(8,161 |
) |
|
(43.0 |
)% |
|
$ |
67,336 |
|
$ |
69,148 |
|
$ |
(1,812 |
) |
|
(2.6 |
)% |
||||
Operating margin (GAAP) |
|
|
12.8 |
% |
|
16.7 |
% |
|
|
|
|
|
|
17.2 |
% |
|
17.5 |
% |
|
|
|
|
||||||||
Operating margin (non-GAAP) |
|
|
13.2 |
% |
|
22.8 |
% |
|
|
|
|
|
|
19.5 |
% |
|
20.4 |
% |
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Home Office and Other: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating loss (GAAP) |
|
$ |
(16,412 |
) |
$ |
(21,560 |
) |
$ |
5,148 |
|
|
23.9 |
% |
|
$ |
(62,044 |
) |
$ |
(101,719 |
) |
$ |
39,675 |
|
|
39.0 |
% |
||||
CEO transition costs |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
6,195 |
|
|
(6,195 |
) |
|
|
||||||
Restructuring expense |
|
|
687 |
|
|
2,986 |
|
|
(2,299 |
) |
|
|
|
|
7,067 |
|
|
8,946 |
|
|
(1,879 |
) |
|
|
||||||
Business acquisition and integration expense |
|
|
6,959 |
|
|
11,661 |
|
|
(4,702 |
) |
|
|
|
|
42,661 |
|
|
53,198 |
|
|
(10,537 |
) |
|
|
||||||
Gain on sale of assets |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
(13,317 |
) |
|
— |
|
|
(13,317 |
) |
|
|
||||||
Adjusted operating loss (non-GAAP) |
|
$ |
(8,766 |
) |
$ |
(6,913 |
) |
$ |
(1,853 |
) |
|
(26.8 |
)% |
|
$ |
(25,633 |
) |
$ |
(33,380 |
) |
$ |
7,747 |
|
|
23.2 |
% |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Adtalem Global Education: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating income (GAAP) |
|
$ |
39,557 |
|
$ |
45,963 |
|
$ |
(6,406 |
) |
|
(13.9 |
)% |
|
$ |
168,170 |
|
$ |
76,746 |
|
$ |
91,424 |
|
|
119.1 |
% |
||||
Deferred revenue adjustment |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
8,561 |
|
|
(8,561 |
) |
|
|
||||||
CEO transition costs |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
6,195 |
|
|
(6,195 |
) |
|
|
||||||
Restructuring expense |
|
|
1,111 |
|
|
8,629 |
|
|
(7,518 |
) |
|
|
|
|
18,817 |
|
|
25,628 |
|
|
(6,811 |
) |
|
|
||||||
Business acquisition and integration expense |
|
|
6,959 |
|
|
11,661 |
|
|
(4,702 |
) |
|
|
|
|
42,661 |
|
|
53,198 |
|
|
(10,537 |
) |
|
|
||||||
Intangible amortization expense |
|
|
12,303 |
|
|
23,307 |
|
|
(11,004 |
) |
|
|
|
|
61,239 |
|
|
97,274 |
|
|
(36,035 |
) |
|
|
||||||
Litigation reserve |
|
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
|
|
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
|
||||||
Gain on sale of assets |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
(13,317 |
) |
|
— |
|
|
(13,317 |
) |
|
|
||||||
Adjusted operating income (non-GAAP) |
|
$ |
69,930 |
|
$ |
89,560 |
|
$ |
(19,630 |
) |
|
(21.9 |
)% |
|
$ |
287,570 |
|
$ |
267,602 |
|
$ |
19,968 |
|
|
7.5 |
% |
||||
Operating margin (GAAP) |
|
|
10.8 |
% |
|
12.7 |
% |
|
|
|
|
|
|
11.6 |
% |
|
5.6 |
% |
|
|
|
|
||||||||
Operating margin (non-GAAP) |
|
|
19.2 |
% |
|
24.8 |
% |
|
|
|
|
|
|
19.8 |
% |
|
19.4 |
% |
|
|
|
|
Adtalem Global Education Inc.
Non-GAAP Adjusted EBITDA by Segment (unaudited) (in thousands) |
|||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Three Months Ended |
Year Ended |
|||||||||||||||||||||||||||
|
June 30, |
June 30, |
|||||||||||||||||||||||||||
|
|
|
|
|
Increase/(Decrease) |
|
|
|
|
Increase/(Decrease) |
|||||||||||||||||||
|
2023 |
|
2022 |
|
$ |
|
% |
|
2023 |
|
2022 |
|
$ |
|
% |
||||||||||||||
Chamberlain: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Operating income (GAAP) |
$ |
35,683 |
|
$ |
41,124 |
|
$ |
(5,441 |
) |
(13.2 |
)% |
$ |
134,685 |
|
$ |
124,414 |
|
$ |
10,271 |
|
8.3 |
% |
|||||||
Restructuring expense |
|
— |
|
|
572 |
|
|
(572 |
) |
|
|
818 |
|
|
2,838 |
|
|
(2,020 |
) |
|
|||||||||
Depreciation |
|
4,279 |
|
|
4,499 |
|
|
(220 |
) |
|
|
17,264 |
|
|
18,547 |
|
|
(1,283 |
) |
|
|||||||||
Stock-based compensation |
|
1,118 |
|
|
1,603 |
|
|
(485 |
) |
|
|
4,719 |
|
|
6,707 |
|
|
(1,988 |
) |
|
|||||||||
Adjusted EBITDA (non-GAAP) |
$ |
41,080 |
|
$ |
47,798 |
|
$ |
(6,718 |
) |
(14.1 |
)% |
$ |
157,486 |
|
$ |
152,506 |
|
$ |
4,980 |
|
3.3 |
% |
|||||||
Adjusted EBITDA margin (non-GAAP) |
|
28.4 |
% |
|
34.1 |
% |
|
|
|
|
27.6 |
% |
|
27.4 |
% |
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Walden: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Operating income (loss) (GAAP) |
$ |
9,809 |
|
$ |
12,442 |
|
$ |
(2,633 |
) |
(21.2 |
)% |
$ |
35,880 |
|
$ |
(5,306 |
) |
$ |
41,186 |
|
NM |
|
|||||||
Deferred revenue adjustment |
|
— |
|
|
— |
|
|
— |
|
|
|
— |
|
|
8,561 |
|
|
(8,561 |
) |
|
|||||||||
Restructuring expense |
|
71 |
|
|
37 |
|
|
34 |
|
|
|
3,245 |
|
|
4,053 |
|
|
(808 |
) |
|
|||||||||
Intangible amortization expense |
|
12,303 |
|
|
23,307 |
|
|
(11,004 |
) |
|
|
61,239 |
|
|
97,274 |
|
|
(36,035 |
) |
|
|||||||||
Litigation reserve |
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
|||||||||
Depreciation |
|
2,189 |
|
|
2,454 |
|
|
(265 |
) |
|
|
9,492 |
|
|
9,255 |
|
|
237 |
|
|
|||||||||
Stock-based compensation |
|
916 |
|
|
721 |
|
|
195 |
|
|
|
3,861 |
|
|
3,029 |
|
|
832 |
|
|
|||||||||
Adjusted EBITDA (non-GAAP) |
$ |
35,288 |
|
$ |
38,961 |
|
$ |
(3,673 |
) |
(9.4 |
)% |
$ |
123,717 |
|
$ |
116,866 |
|
$ |
6,851 |
|
5.9 |
% |
|||||||
Adjusted EBITDA margin (non-GAAP) |
|
25.6 |
% |
|
28.4 |
% |
|
|
|
|
23.2 |
% |
|
24.1 |
% |
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Medical and Veterinary: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Operating income (GAAP) |
$ |
10,477 |
|
$ |
13,957 |
|
$ |
(3,480 |
) |
(24.9 |
)% |
$ |
59,649 |
|
$ |
59,357 |
|
$ |
292 |
|
0.5 |
% |
|||||||
Restructuring expense |
|
353 |
|
|
5,034 |
|
|
(4,681 |
) |
|
|
7,687 |
|
|
9,791 |
|
|
(2,104 |
) |
|
|||||||||
Depreciation |
|
3,108 |
|
|
3,393 |
|
|
(285 |
) |
|
|
12,475 |
|
|
13,890 |
|
|
(1,415 |
) |
|
|||||||||
Stock-based compensation |
|
712 |
|
|
922 |
|
|
(210 |
) |
|
|
3,003 |
|
|
3,896 |
|
|
(893 |
) |
|
|||||||||
Adjusted EBITDA (non-GAAP) |
$ |
14,650 |
|
$ |
23,306 |
|
$ |
(8,656 |
) |
(37.1 |
)% |
$ |
82,814 |
|
$ |
86,934 |
|
$ |
(4,120 |
) |
(4.7 |
)% |
|||||||
Adjusted EBITDA margin (non-GAAP) |
|
17.8 |
% |
|
28.0 |
% |
|
|
|
|
23.9 |
% |
|
25.7 |
% |
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Home Office and Other: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Operating loss (GAAP) |
$ |
(16,412 |
) |
$ |
(21,560 |
) |
$ |
5,148 |
|
23.9 |
% |
$ |
(62,044 |
) |
$ |
(101,719 |
) |
$ |
39,675 |
|
39.0 |
% |
|||||||
CEO transition costs |
|
— |
|
|
— |
|
|
— |
|
|
|
— |
|
|
6,195 |
|
|
(6,195 |
) |
|
|||||||||
Restructuring expense |
|
687 |
|
|
2,986 |
|
|
(2,299 |
) |
|
|
7,067 |
|
|
8,946 |
|
|
(1,879 |
) |
|
|||||||||
Business acquisition and integration expense |
|
6,959 |
|
|
11,661 |
|
|
(4,702 |
) |
|
|
42,661 |
|
|
53,198 |
|
|
(10,537 |
) |
|
|||||||||
Gain on sale of assets |
|
— |
|
|
— |
|
|
— |
|
|
|
(13,317 |
) |
|
— |
|
|
(13,317 |
) |
|
|||||||||
Depreciation |
|
381 |
|
|
757 |
|
|
(376 |
) |
|
|
2,344 |
|
|
2,882 |
|
|
(538 |
) |
|
|||||||||
Stock-based compensation |
|
645 |
|
|
761 |
|
|
(116 |
) |
|
|
2,716 |
|
|
2,784 |
|
|
(68 |
) |
|
|||||||||
Adjusted EBITDA (non-GAAP) |
$ |
(7,740 |
) |
$ |
(5,395 |
) |
$ |
(2,345 |
) |
(43.5 |
)% |
$ |
(20,573 |
) |
$ |
(27,714 |
) |
$ |
7,141 |
|
25.8 |
% |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Adtalem Global Education: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Net income (GAAP) |
$ |
22,244 |
|
$ |
6,746 |
|
$ |
15,498 |
|
229.7 |
% |
$ |
93,358 |
|
$ |
310,991 |
|
$ |
(217,633 |
) |
(70.0 |
)% |
|||||||
Net loss (income) from discontinued operations |
|
1,306 |
|
|
(5,609 |
) |
|
6,915 |
|
|
|
8,394 |
|
|
(346,946 |
) |
|
355,340 |
|
|
|||||||||
Interest expense |
|
15,294 |
|
|
19,441 |
|
|
(4,147 |
) |
|
|
63,100 |
|
|
129,348 |
|
|
(66,248 |
) |
|
|||||||||
Other (income) expense, net |
|
(3,664 |
) |
|
1,327 |
|
|
(4,991 |
) |
|
|
(6,965 |
) |
|
(1,108 |
) |
|
(5,857 |
) |
|
|||||||||
Provision for (benefit from) income taxes |
|
4,377 |
|
|
24,058 |
|
|
(19,681 |
) |
|
|
10,283 |
|
|
(15,539 |
) |
|
25,822 |
|
|
|||||||||
Operating income (GAAP) |
|
39,557 |
|
|
45,963 |
|
|
(6,406 |
) |
|
|
168,170 |
|
|
76,746 |
|
|
91,424 |
|
|
|||||||||
Depreciation and amortization |
|
22,260 |
|
|
34,410 |
|
|
(12,150 |
) |
|
|
102,814 |
|
|
141,848 |
|
|
(39,034 |
) |
|
|||||||||
Stock-based compensation |
|
3,391 |
|
|
4,007 |
|
|
(616 |
) |
|
|
14,299 |
|
|
16,416 |
|
|
(2,117 |
) |
|
|||||||||
Deferred revenue adjustment |
|
— |
|
|
— |
|
|
— |
|
|
|
— |
|
|
8,561 |
|
|
(8,561 |
) |
|
|||||||||
CEO transition costs |
|
— |
|
|
— |
|
|
— |
|
|
|
— |
|
|
6,195 |
|
|
(6,195 |
) |
|
|||||||||
Restructuring expense |
|
1,111 |
|
|
8,629 |
|
|
(7,518 |
) |
|
|
18,817 |
|
|
25,628 |
|
|
(6,811 |
) |
|
|||||||||
Business acquisition and integration expense |
|
6,959 |
|
|
11,661 |
|
|
(4,702 |
) |
|
|
42,661 |
|
|
53,198 |
|
|
(10,537 |
) |
|
|||||||||
Litigation reserve |
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
|||||||||
Gain on sale of assets |
|
— |
|
|
— |
|
|
— |
|
|
|
(13,317 |
) |
|
— |
|
|
(13,317 |
) |
|
|||||||||
Adjusted EBITDA (non-GAAP) |
$ |
83,278 |
|
$ |
104,670 |
|
$ |
(21,392 |
) |
(20.4 |
)% |
$ |
343,444 |
|
$ |
328,592 |
|
$ |
14,852 |
|
4.5 |
% |
|||||||
Adjusted EBITDA margin (non-GAAP) |
|
22.8 |
% |
|
29.0 |
% |
|
|
|
|
23.7 |
% |
|
23.8 |
% |
|
|
|
Adtalem Global Education Inc.
Non-GAAP Earnings Disclosure (unaudited) (in thousands, except per share data) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
June 30, |
|
June 30, |
||||||||||||
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Net income (GAAP) |
|
$ |
22,244 |
|
|
$ |
6,746 |
|
|
$ |
93,358 |
|
|
$ |
310,991 |
|
Deferred revenue adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,561 |
|
CEO transition costs |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6,195 |
|
Restructuring expense |
|
|
1,111 |
|
|
|
8,629 |
|
|
|
18,817 |
|
|
|
25,628 |
|
Business acquisition and integration expense |
|
|
6,959 |
|
|
|
11,661 |
|
|
|
42,661 |
|
|
|
53,198 |
|
Intangible amortization expense |
|
|
12,303 |
|
|
|
23,307 |
|
|
|
61,239 |
|
|
|
97,274 |
|
Gain on sale of assets |
|
|
— |
|
|
|
— |
|
|
|
(13,317 |
) |
|
|
— |
|
Pre-acquisition interest expense, write-off of debt discount and issuance costs, gain on extinguishment of debt, litigation reserve, and investment impairment |
|
|
10,000 |
|
|
|
4,699 |
|
|
|
19,226 |
|
|
|
48,804 |
|
Net tax benefit related to a valuation allowance release |
|
|
— |
|
|
|
— |
|
|
|
(6,184 |
) |
|
|
— |
|
Income tax impact on non-GAAP adjustments (1) |
|
|
(8,656 |
) |
|
|
9,188 |
|
|
|
(31,997 |
) |
|
|
(51,683 |
) |
Net loss (income) from discontinued operations |
|
|
1,306 |
|
|
|
(5,609 |
) |
|
|
8,394 |
|
|
|
(346,946 |
) |
Adjusted net income (non-GAAP) |
|
$ |
45,267 |
|
|
$ |
58,621 |
|
|
$ |
192,197 |
|
|
$ |
152,022 |
|
(1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
June 30, |
|
June 30, |
||||||||||||
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Earnings per share, diluted (GAAP) |
|
$ |
0.50 |
|
|
$ |
0.15 |
|
|
$ |
2.05 |
|
|
$ |
6.43 |
|
Effect on diluted earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Deferred revenue adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.18 |
|
CEO transition costs |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.13 |
|
Restructuring expense |
|
|
0.03 |
|
|
|
0.19 |
|
|
|
0.41 |
|
|
|
0.53 |
|
Business acquisition and integration expense |
|
|
0.16 |
|
|
|
0.25 |
|
|
|
0.94 |
|
|
|
1.09 |
|
Intangible amortization expense |
|
|
0.28 |
|
|
|
0.51 |
|
|
|
1.34 |
|
|
|
1.99 |
|
Gain on sale of assets |
|
|
— |
|
|
|
— |
|
|
|
(0.29 |
) |
|
|
— |
|
Pre-acquisition interest expense, write-off of debt discount and issuance costs, gain on extinguishment of debt, litigation reserve, and investment impairment |
|
|
0.23 |
|
|
|
0.10 |
|
|
|
0.42 |
|
|
|
1.00 |
|
Net tax benefit related to a valuation allowance release |
|
|
— |
|
|
|
— |
|
|
|
(0.14 |
) |
|
|
— |
|
Income tax impact on non-GAAP adjustments (1) |
|
|
(0.20 |
) |
|
|
0.20 |
|
|
|
(0.70 |
) |
|
|
(1.06 |
) |
Net loss (income) from discontinued operations |
|
|
0.03 |
|
|
|
(0.12 |
) |
|
|
0.18 |
|
|
|
(7.17 |
) |
Adjusted earnings per share, diluted (non-GAAP) |
|
$ |
1.03 |
|
|
$ |
1.28 |
|
|
$ |
4.21 |
|
|
$ |
3.11 |
|
Diluted shares used in non-GAAP EPS calculation |
|
|
44,129 |
|
|
|
45,758 |
|
|
|
45,600 |
|
|
|
48,804 |
|
Note: May not sum due to rounding. |
||||||||||||||||
(1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. |
Adtalem Global Education Inc.
Non-GAAP Free Cash Flow Disclosure (unaudited) (in thousands) |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||||||||||
|
|
FY23 |
|
FY22 |
|
FY23 |
|
FY23 |
|
FY23 |
|
FY23 |
|
FY22 |
||||||||||||||
|
|
Q4 |
|
Q4 |
|
Q4 |
|
Q3 |
|
Q2 |
|
Q1 |
|
Q4 |
||||||||||||||
Net cash provided by operating activities-continuing operations (GAAP) |
|
$ |
55,863 |
|
|
$ |
105,231 |
|
|
$ |
205,684 |
|
|
$ |
255,052 |
|
|
$ |
225,247 |
|
|
$ |
225,972 |
|
|
$ |
164,002 |
|
Capital expenditures |
|
|
(17,952 |
) |
|
|
(8,805 |
) |
|
|
(37,008 |
) |
|
|
(27,861 |
) |
|
|
(26,029 |
) |
|
|
(29,914 |
) |
|
|
(31,054 |
) |
Free cash flow (non-GAAP) |
|
$ |
37,911 |
|
|
$ |
96,426 |
|
|
$ |
168,676 |
|
|
$ |
227,191 |
|
|
$ |
199,218 |
|
|
$ |
196,058 |
|
|
$ |
132,948 |
|
Adtalem Global Education Inc. Non-GAAP Net Leverage Disclosure (unaudited) (in thousands) |
||||
|
|
|
|
|
|
|
Year Ended |
||
|
|
June 30, 2023 |
||
Adtalem Global Education: |
|
|
|
|
Net income (GAAP) |
|
$ |
93,358 |
|
Net loss from discontinued operations |
|
|
8,394 |
|
Interest expense |
|
|
63,100 |
|
Other income, net |
|
|
(6,965 |
) |
Provision for income taxes |
|
|
10,283 |
|
Depreciation and amortization |
|
|
102,814 |
|
Stock-based compensation |
|
|
14,299 |
|
Restructuring expense |
|
|
18,817 |
|
Business acquisition and integration expense |
|
|
42,661 |
|
Litigation reserve |
|
|
10,000 |
|
Gain on sale of assets |
|
|
(13,317 |
) |
Adjusted EBITDA (non-GAAP) |
|
$ |
343,444 |
|
|
|
|
|
|
|
|
June 30, 2023 |
||
Long-term debt |
|
$ |
708,283 |
|
Less: Cash and cash equivalents |
|
|
(273,689 |
) |
Net debt (non-GAAP) |
|
$ |
434,594 |
|
|
|
|
|
|
Net leverage (non-GAAP) |
|
|
1.3 x |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230810844297/en/
Investor Contact
Jay Spitzer and Chandrika Nigam
Investor.Relations@Adtalem.com
+1 312-906-6600
Media Contact
Talisha Holmes
AdtalemMedia@Adtalem.com
+1 872-270-0331
Source: Adtalem Global Education Inc.
FAQ
What are Adtalem's FY 2023 adjusted EPS and revenue?
What is Adtalem's FY 2024 revenue guidance?
How much did Adtalem reduce its gross debt in FY 2023?
What is the growth rate of Adtalem's fourth-quarter revenue?